The accompanying table includes 47 U.S.-listed companies with market caps over $10B and dividend yields over 5%, excluding all companies from the following sectors or industry groups: finance, insurance, consumer cyclical products, retailers, and basic materials in favor of healthcare, consumer staples such as tobacco, telecom services, energy, and utilities. Also, the following dividend ETFs are included in the table as a comparison:
1.) iShares Dow Jones Select Dividend (DVY) 2.) WisdomTree Dividend Top 1
MRK's projected P/E is 8.05 Industry (Drug Manufacturers - Major) average projected P/E 9.76 Implies a projected stock price of $34.55
MRK's PEG is 1.53 MRK's projected earnings growth rate is 5.26% Industry (Drug Manufacturers - Major) average PEG is 2.24 Implies a projected stock price of $41.73
More analysis source, calculations, and other info:
We have finally reached a point where all denial is gone and we are ready to admit the error of our ways. Sure, there were plenty of folks ringing the alarm bells years ago, but universal acceptance of the fundamental economic calamity that faces us from every corner of the world, and every person with two cents to rub together, has just now ...
This post is part of a series in which TheStockAdvisors.com asked financial experts to name their top stock pick if McCain or if Obama wins the election.
Based on their campaign promises and party platforms
The following two-part article puts forth ten stock ideas that I believe would be better off in your investment portfolio than one comprised primarily of Certificates of Deposits (CDs) or bonds, or even government treasuries. This is not to say that these do not have value or offer some level of security, but they are long term losers.
A basket of high yielding-high quality stocks can offer a higher return
Merck & Co., Inc. provides various products for human and animal health in the United States and internationally. The company’s Pharmaceutical segment includes human health pharmaceutical products, such as therapeutic and preventive agents. Its products comprise Singulair, a leukotriene receptor antagonist for the treatment of asthma and allergic rhinitis; Cozaar, Hyzaar, Vasotec, a
Analysts have clearly under-estimated the power of what three new big drugs such as Vytorin (cholesterol), Januvia (diabetes), and Gardasil (cervical cancer vaccine) can do.
Recap of CNBC's Fast Money, Tuesday May 6. Click on a stock ticker for more analysis.
<!--more-->
Market Overview: Burlington Northern Santa Fe (BNI), Google (GOOG)
Friday’s selloff saw the Dow stumble 1.22%, the S &P fall 0.8% and the Nasdaq trading down 0.3%. Guy Adami says the market hasn’t bottomed yet, but continues to like railroad stocks like BNI as well as natural gas. Najarian noted Google’s spectacular $40 drop and said the tech horsemen need a rest. Jeff Macke wouldn’t buy stocks unless they fall on a panic. The group looked at the Volatility Index and Najarian said when there
4/30 - "Last week the Committee for Medicinal Products for Human Consumption (CHMP) of the European Medicines Agency (EMEA) recommended approval of Tredaptive (formerly Cordaptive), Merck’s combination extended-release niacin with a novel flushing inhibitor (a prostaglandin D2 antagonist). However, FDA issued a Not Approvable, likely owing to safety concerns with the product; we are therefore reducing our estimates."
"Niacin-based therapies have been available for some time as both a food supplement and an ethical pharmaceutical, but their utilization remains marginal compared to other li...
3/31 - "Zetia/Vytorin Sales Estimates Reduced — We believe that today’s outcome will have a meaningfully negative impact on the prescribing habits in the US, and, to a lesser extent, in non-US markets. Consequently, our 2007-10E cholesterol franchise sales CAGR decreases to -3% (previously +4%) for WW sales and - 11% (previously -2%) for US sales."
"We believe the panel’s recommendation to shift the therapeutic focus away from Zetia creates a real need for viable alternatives in the cholesterol reduction market. This may potentially expand the opportunity for MRK’s Cordaptive, and mitigate...
my decision for MRK is based upon broken promises. by this i mean, (MRK) Don't announce that you have some kind of aids drug in the works if the probablility of success is next to nothing. another pharmaceutical co. will eventually capitalize off of this mistake. by all means, there is still a future for this co.i just would wait for the drop to buy again.
Merck's going through some bad times because of the Vioxx litigation but this is a legacy company that is built to weather such storms and come out of the other side leaner and meaner than its competitors. Merck has a significant drug which is a vaccination for the HPV virus that causes genital warts and cervical cancer. It has passed clinical trials and is ramping up for mass marketing. This is a multi-billion dollar global market which will help the company's 5-year growth prospects and position it better for growth in the next decade through major acquisitions.
Portfolio results thru 8/8/08
- Portfolio at www.updown.com - started 1/11/08
9.8% return includes dividends and commission.
Started socialpicks on 6/30. some stocks here are not in...
Stock update and watch list 7/29/08
- Due to difficulties understanding the socialpicks system regarding changing rating from buy to hold and thus resetting the performance, I wanted to sum...
Data powered by QuoteMedia.
All Rights Reserved.
Data delayed 15 to 20 minutes unless otherwise indicated.
Terms of Use.
None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.
We have finally reached a point where all denial is gone and we are ready to admit the error of our ways. Sure, there were plenty of folks ringing the alarm bells years ago, but universal acceptance of the fundamental economic calamity that faces us from every corner of the world, and every person with two cents to rub together, has just now ...
The following two-part article puts forth ten stock ideas that I believe would be better off in your investment portfolio than one comprised primarily of Certificates of Deposits (CDs) or bonds, or even government treasuries. This is not to say that these do not have value or offer some level of security, but they are long term losers.
